UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Application of the anatomical chemical system/defined daily doses: Challenges and way forward for resource‐limited countries

Journal of clinical pharmacy and therapeutics, 2022-02, Vol.47 (2), p.135-138

2022

Volltextzugriff (PDF)

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

PloS one, 2014-01, Vol.9 (1), p.e86919

2014

Volltextzugriff (PDF)

A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients

BMC medical informatics and decision making, 2018-09, Vol.18 (1), p.77-77, Article 77

2018

Volltextzugriff (PDF)

A novel polymorphism in ABCB1 gene, CYP2B66 and sex predict single‐dose efavirenz population pharmacokinetics in Ugandans

British journal of clinical pharmacology, 2009-11, Vol.68 (5), p.690-699

2009

Volltextzugriff (PDF)

Evaluation of the effects of Artemisia Annua L. and Moringa Oleifera Lam. on CD4 count and viral load among PLWH on ART at Mbarara Regional Referral Hospital: a double-blind randomized controlled clinical trial

AIDS research and therapy, 2024-04, Vol.21 (1), p.22-10, Article 22

2024

Volltextzugriff (PDF)

Expanding regulatory science: Regulatory complementarity and reliance

Clinical and translational science, 2024-01, Vol.17 (1), p.e13683-n/a

2024

Volltextzugriff (PDF)

Strategies to Reduce Mortality Among Children Living With HIV and Children Exposed to HIV but Are Uninfected, Admitted With Severe Acute Malnutrition at Mulago Hospital, Uganda (REDMOTHIV): A Mixed Methods Study

Frontiers in pediatrics, 2022-06, Vol.10, p.880355-880355

2022

Volltextzugriff (PDF)

Regulatory insight from low-income countries

Science (American Association for the Advancement of Science), 2022-10, Vol.378 (6617), p.256-256

2022

Volltextzugriff (PDF)

Antiretroviral drugs found in pork on Ugandan market: Implications for HIV/AIDS treatment

One health, 2020-06, Vol.9, p.100125-100125, Article 100125

2020

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Clinical infectious diseases, 2018-08, Vol.67 (5), p.785-790

2018

Volltextzugriff (PDF)

The challenge of paediatric efavirenz dosing: implications and way forward for the sub-Saharan Africa

AIDS (London), 2014-08, Vol.28 (13), p.1855-1857

Mukonzo, Jackson K

2014

Volltextzugriff (PDF)

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

BMC infectious diseases, 2013-06, Vol.13 (1), p.261-261, Article 261

2013

Volltextzugriff (PDF)

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB–rifampicin sensitivity among Ugandan patients

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020-02, Vol.114 (2), p.107-114

2020

Volltextzugriff (PDF)

Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans

Therapeutic drug monitoring, 2010-06, Vol.32 (3), p.346

2010

Volltextzugriff (PDF)

Maximizing Knowledge Extraction From Patient‐Reported Outcome Data Using Exposure‐Outcome Item Response Modeling Approach: Understanding Efavirenz‐Induced Central Nervous System Toxicity

Journal of clinical pharmacology, 2020-06, Vol.60 (6), p.711-721

2020

Volltextzugriff (PDF)

A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro

In silico pharmacology, 2023-10, Vol.11 (1), p.31-31, Article 31

2023

Volltextzugriff (PDF)

Stimulus – Response mechanistic modeling of pharmacodynamic drug-drug interaction: Extension of the operational receptor model of agonism

Informatics in medicine unlocked, 2022, Vol.28, p.100813, Article 100813

2022

Volltextzugriff (PDF)

Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

Journal of clinical pharmacology, 2015-11, Vol.55 (11), p.1229-1235

2015

Volltextzugriff (PDF)

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population

Pharmacogenomics, 2016-04, Vol.17 (6), p.603-613

2016

Volltextzugriff (PDF)

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure

Pharmacogenomics, 2014-08, Vol.15 (11), p.1423-1435

2014

Volltextzugriff (PDF)

Over-the-counter suboptimal dispensing of antibiotics in Uganda

Journal of multidisciplinary healthcare, 2013-01, Vol.6 (default), p.303-310

2013

Volltextzugriff (PDF)

Transition modeling of neuropsychiatric impairment in HIV

Computers in biology and medicine, 2016-06, Vol.73, p.141-146

2016

Volltextzugriff (PDF)

HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects

Clinical pharmacokinetics, 2011-08, Vol.50 (8), p.531-540

2011

Volltextzugriff (PDF)

Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine–Pyrimethamine Disposition Among Ugandan Pregnant Women

Drugs in R&D, 2015-12, Vol.15 (4), p.351-362

2015

Volltextzugriff (PDF)

Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials

HIV/AIDS (Auckland), 2018-01, Vol.10, p.151-155

2018

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Application of the anatomical chemical system/defined daily doses: Challenges and way forward for resource‐limited countries

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients

A novel polymorphism in ABCB1 gene, CYP2B66 and sex predict single‐dose efavirenz population pharmacokinetics in Ugandans

Evaluation of the effects of Artemisia Annua L. and Moringa Oleifera Lam. on CD4 count and viral load among PLWH on ART at Mbarara Regional Referral Hospital: a double-blind randomized controlled clinical trial

Expanding regulatory science: Regulatory complementarity and reliance

Strategies to Reduce Mortality Among Children Living With HIV and Children Exposed to HIV but Are Uninfected, Admitted With Severe Acute Malnutrition at Mulago Hospital, Uganda (REDMOTHIV): A Mixed Methods Study

Regulatory insight from low-income countries

Antiretroviral drugs found in pork on Ugandan market: Implications for HIV/AIDS treatment

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

The challenge of paediatric efavirenz dosing: implications and way forward for the sub-Saharan Africa

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB–rifampicin sensitivity among Ugandan patients

Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans

Maximizing Knowledge Extraction From Patient‐Reported Outcome Data Using Exposure‐Outcome Item Response Modeling Approach: Understanding Efavirenz‐Induced Central Nervous System Toxicity

A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro

Stimulus – Response mechanistic modeling of pharmacodynamic drug-drug interaction: Extension of the operational receptor model of agonism

Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure

Over-the-counter suboptimal dispensing of antibiotics in Uganda

Transition modeling of neuropsychiatric impairment in HIV

HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects

Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine–Pyrimethamine Disposition Among Ugandan Pregnant Women

Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials

Suchergebnisse filtern